{"entity":{"id":"nct07109414","kind":"trial","name":"Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)","aka":["ULTIMUS-1"],"tldr":"A phase 2/3 trial of NP-G2-044 in ovarian cancer, run by Novita Pharmaceuticals, Inc., active and no longer recruiting.","summary":"Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1) is a phase 2/3 interventional study registered as NCT07109414 by Novita Pharmaceuticals, Inc., with 380 participants enrolled, started 2025-12-29 and due to reach its primary completion in 2028-10-25. Interventions recorded: NP-G2-044 and PLD.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07109414","url":"https://clinicaltrials.gov/study/NCT07109414"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian","platinum-resistant-ovarian-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy","topoisomerase-inhibitors"],"targets":[],"drugs":["pegylated-liposomal-doxorubicin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07109414","phase":"2/3","setting":"Randomized Phase 2/3 Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)","sponsor":"Novita Pharmaceuticals, Inc.","started":"2025-12-29","startedType":"actual","enrolled":380,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07109414/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"platinum-resistant-ovarian-cancer","kind":"cancer","name":"Platinum-resistant ovarian cancer","route":"/cancers/platinum-resistant-ovarian-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"pegylated-liposomal-doxorubicin","kind":"drug","name":"Pegylated liposomal doxorubicin","route":"/drugs/pegylated-liposomal-doxorubicin/"}]}}